Abstract
The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.
Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.
Reviews on Recent Clinical Trials
Title:Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Volume: 11 Issue: 2
Author(s): Marlana Orloff, Ryan Weight, Matias E. Valsecchi and Takami Sato
Affiliation:
Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.
Abstract: The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.
Export Options
About this article
Cite this article as:
Orloff Marlana, Weight Ryan, E. Valsecchi Matias and Sato Takami, Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330120712
DOI https://dx.doi.org/10.2174/1574887111666160330120712 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Does Hepatic Steatosis Affect Drug Metabolizing Enzymes in the Liver?
Current Drug Metabolism Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Identification of Imidazoquinoline Derivatives as Potent Antiglioma Agents
Medicinal Chemistry A Mini-review on HER2 Positive Breast Cancer and its Metastasis: Resistance and Treatment Strategies
Current Nanomedicine Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Editorial (Thematic Issue: Gene Transfer by Electric Fields)
Current Gene Therapy TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in Developing Photosensitizers for Photodynamic Cancer Therapy
Combinatorial Chemistry & High Throughput Screening Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Ultrasound-Directed Drug Delivery
Current Pharmaceutical Biotechnology Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine